Nova BioGenetics Inc. (fka NVBG)

[GGraessle]

Nova BioGenetics Inc. Completes Reverse Merger with Healthcare Network Solutions and Announces New Stock Trading Symbol
Wednesday August 13, 2:58 pm ET


ATLANTA--(BUSINESS WIRE)--Aug. 13, 2003--Nova BioGenetics Inc. F/K/A Healthcare Network Solutions (OTC Bulletin Board: HNWS - News) The Board of Directors of Healthcare Network Solutions ("HNS") and Nova BioGenetics Inc. ("Nova") are pleased to announce that Nova has completed the acquisition of a controlling interest in HNS through a reverse merger, with Nova being the surviving business entity.
Concurrent with the merger, HNS' officer and directors have resigned in favor of a new management team and Board of Directors nominated by Nova. Officers and Directors of Nova now own/control more than 60% of the Company's issued and outstanding stock.

The Company also wishes to report that it has received regulatory approvals of its application for a name change (to "Nova BioGenetics Inc.") and new trading symbol which better-reflects the Company's new business focus. Effective at the start of trading August 14, 2003, shares of Nova will begin trading under the symbol (OTC Bulletin Board: NVBG - News) and all pricing should be adjusted, as the reverse of 1 for 8.9 takes place at the open.

Investors can access the website to view news releases and independent third party research reports, read Letters to shareholders, and learn more about Nova's complete range of biopharmaceutical products at www.novabiogenetics.com or contact Tim Moses, #770 650-6508.

About Nova BioGenetics Inc.:

Nova BioGenetics Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies, used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.

While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides.

Further information on Nova and its line of products can be found by visiting the firm's web site at http://www.novabiogenetics.com, Ph.# 770-650-6508, Fax # [phone], contact Tim Moses, Director of Public Securities.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Tim Moses, 770-650-6508
Fax: [phone]
http://www.novabiogenetics.com